(9.15.2.9) Reporting year figure

1657539

(9.15.2.10) Target status in reporting year

Select from:

☑ Underway

(9.15.2.11) % of target achieved relative to base year

57

(9.15.2.12) Global environmental treaties/initiatives/ frameworks aligned with or supported by this target

Select all that apply

☑ Sustainable Development Goal 6

(9.15.2.13) Explain target coverage and identify any exclusions

The scope of our data collection in 2024 includes 15 sites composed of manufacturing, R&D, and distribution facilities in the United States (including Puerto Rico), Netherlands, United Kingdom, Ireland, Canada, and Singapore. These facilities account for approximately 87% of our operations based on square footage. The remaining 13% is primarily shared office and administrative spaces. Amgen is not a significant consumer of water in administrative spaces when compared to our manufacturing, R&D, and distribution facilities. Water and waste reductions are measured against a 2019 baseline and take into account only verified reduction projects and not changes associated with the contraction or expansion of the Company.

(9.15.2.14) Plan for achieving target, and progress made to the end of the reporting year

Amgen is implementing water efficiency projects to achieve its 2027 water ambition. Examples include increasing the use of recycled water, implementing improved reverse osmosis technologies, improving manufacturing processes like clean-in-place (CIP) cycles, and installing low-flow fixtures and drought-friendly landscaping to reduce water consumption. Additionally, Amgen Ecovation™ integrates innovation and sustainability into the upfront design and execution of our new laboratory, manufacturing, and administrative buildings, resulting in reduced water consumption. In 2024, we continued our internal Sustainability Maturity Matrix that outlines best practices for sites to reduce water use. This tool also allows global implementation, measurement and tracking of these practices by site and supports idea exchange. In 2024, we achieved 488,000 CM of cumulative water reductions across the Amgen enterprise as we make steady progress toward our goal to reduce 858,500 CM by 2027.

(9.15.2.16) Further details of target

Water reductions across our Amgen network are primarily achieved through the implementation of water-efficiency projects, design of innovative new facilities, water treatment and recycling efforts, and other strategic initiatives such as the prioritization of our water-stressed sites. For instance, in 2024 we saved 91,000 CM of water via optimized control of an ultra-high-purity water production at our Puerto Rico manufacturing facility. Amgen has created an internal enterprise analytics tool to empower our facilities to visualize the different water-efficiency projects being executed across the network and historical water efficiency projects. This tool further enables the visualization of site-specific water consumption on a geographic map and building-specific water consumption for our largest facilities. Cumulatively across the Amgen enterprise we achieved 488,000 CM of water reductions through our water efficiency/reduction projects in 2024.
[Add row]

C10. Environmental performance - Plastics

(10.1) Do you have plastics-related targets, and if so what type?

(10.1.1) Targets in place

Select from:

☑ Yes

(10.1.2) Target type and metric

Plastic packaging

☑ Other plastic packaging target, please specify :Transition to a fully paper-based secondary packaging where possible

(10.1.3) Please explain

We are executing on an initiative to transition secondary plastic packaging to 100% paper-based packaging where possible by 2030.
[Fixed row]

(10.2) Indicate whether your organization engages in the following activities.

Production/commercialization of plastic polymers (including plastic converters)

(10.2.1) Activity applies

Select from:

☑ No

(10.2.2) Comment

N/A

Production/commercialization of durable plastic goods and/or components (including mixed materials)

(10.2.1) Activity applies

Select from:

☑ No

(10.2.2) Comment

N/A

Usage of durable plastics goods and/or components (including mixed materials)

(10.2.1) Activity applies

Select from:

☑ Yes

(10.2.2) Comment

Amgen uses durable plastic goods in the manufacturing of our products as required by regulatory bodies. For instance, polystyrene plunger rods and polycarbonate in autoinjectors are used because of their chemical resistance.

Production/commercialization of plastic packaging

(10.2.1) Activity applies

Select from:

☑ No

(10.2.2) Comment

N/A

Production/commercialization of goods/products packaged in plastics

(10.2.1) Activity applies

Select from:

☑ Yes

(10.2.2) Comment

Many of our goods are packaged in plastic or the packaging contains plastic components to ensure the safety of the customer and proper delivery of the drug.

Provision/commercialization of services that use plastic packaging (e.g., food services)

(10.2.1) Activity applies

Select from:

☑ Yes

(10.2.2) Comment

We produce drugs that utilize plastic packaging like plastic tamper evident labels and plastic trays to keep the product in place during distribution.

Provision of waste management and/or water management services

(10.2.1) Activity applies

Select from:

☑ No

(10.2.2) Comment

N/A

Provision of financial products and/or services for plastics-related activities

(10.2.1) Activity applies

Select from:

☑ No

(10.2.2) Comment

N/A

Other activities not specified

(10.2.1) Activity applies

Select from:

☑ No

(10.2.2) Comment

N/A
[Fixed row]

(10.4) Provide the total weight of plastic durable goods and durable components produced, sold and/or used, and indicate the raw material content.

Durable goods and durable components used

(10.4.1) Total weight during the reporting year (Metric tons)

3920

(10.4.2) Raw material content percentages available to report

Select all that apply

☑ % virgin fossil-based content

(10.4.3) % virgin fossil-based content

100

(10.4.7) Please explain

This value incorporates the amount of plastic used in manufacturing of drug substance in Amgen-owned manufacturing facilities and the amount of plastic packaging in primary containers and secondary packaging used to safely deliver drugs to the patient from owned facilities.
[Fixed row]

(10.5) Provide the total weight of plastic packaging sold and/or used and indicate the raw material content.

Plastic packaging used

(10.5.1) Total weight during the reporting year (Metric tons)

610

(10.5.2) Raw material content percentages available to report

Select all that apply
☑ % virgin fossil-based content

(10.5.3) % virgin fossil-based content

100

(10.5.7) Please explain

Amgen packages drugs in a combination of paper and plastic packaging that includes necessary literature relating to the drug and its use. Currently, plastic packaging is not sourced from renewable or recycled sources due to potential quality impact uncertainty associated with non-virgin plastic.
[Fixed row]

(10.5.1) Indicate the circularity potential of the plastic packaging you sold and/or used.

Plastic packaging used

(10.5.1.1) Percentages available to report for circularity potential

Select all that apply

☑ % reusable

☑ % technically recyclable

☑ % recyclable in practice and at scale

(10.5.1.2) % of plastic packaging that is reusable

0

(10.5.1.3) % of plastic packaging that is technically recyclable

15

(10.5.1.4) % of plastic packaging that is recyclable in practice at scale

0.4

(10.5.1.5) Please explain

Amgen products are packaged in a combination of paper and plastic configurations which hold different recyclability potential. These recyclability values only pertain to product packaging.
[Fixed row]

(10.6) Provide the total weight of waste generated by the plastic you produce, commercialize, use and/or process and indicate the end-of-life management pathways.

Usage of plastic

(10.6.1) Total weight of waste generated during the reporting year (Metric tons)

3920

(10.6.2) End-of-life management pathways available to report

Select all that apply

☑ Recycling

☑ Waste to Energy

☑ Incineration

☑ Landfill

(10.6.4) % recycling

60

(10.6.6) % waste to energy

29

(10.6.7) % incineration

0

(10.6.8) % landfill

11

(10.6.12) Please explain

These numbers represent the total amount of plastic generated from drug substance manufacturing and plastic from primary containers and secondary packaging components. The End-of-Life pathway is only representative of drug substance plastics because Amgen is able to manage these pathways. Amgen provides recommendations for proper disposal of products/devices. Amgen provides and is part of consortia for device takeback programs, including mail-back for US home-administered sharps products.
[Fixed row]

C11. Environmental performance - Biodiversity

(11.2) What actions has your organization taken in the reporting year to progress your biodiversity-related commitments?

(11.2.1) Actions taken in the reporting period to progress your biodiversity-related commitments

Select from:

☑ Yes, we are taking actions to progress our biodiversity-related commitments

(11.2.2) Type of action taken to progress biodiversity- related commitments

Select all that apply

☑ Land/water protection

☑ Land/water management

☑ Species management

☑ Education & awareness

☑ Other, please specify :Biodiversity risk assessments; Biodiversity Statement

[Fixed row]

(11.3) Does your organization use biodiversity indicators to monitor performance across its activities?

	Does your organization use indicators to monitor biodiversity performance?
	Select from: ☑ No, we do not use indicators, but plan to within the next two years

[Fixed row]

(11.4) Does your organization have activities located in or near to areas important for biodiversity in the reporting year?

Legally protected areas

(11.4.1) Indicate whether any of your organization's activities are located in or near to this type of area important for biodiversity

Select from:

☑ Yes (partial assessment)

(11.4.2) Comment

In 2023, Amgen performed an initial gap analysis aligned with the Taskforce for Nature-Related Financial Disclosures framework to better understand potential areas to further protect nature and biodiversity. We completed a screening-level biodiversity risk assessment for 17 Amgen facilities and six supplier sites. The sites represent ecologically diverse regions and critical operations at each step of Amgen's value chain. This assessment is helping Amgen determine possible site-specific biodiversity risks and opportunities and will form the foundation for prioritizing future action. In 2024, Amgen performed a WWF Biodiversity Risk Filter assessment to identify prioritized, function-based site biodiversity risks and impacts for key sites. We also performed a multi-factor site biodiversity area species impact assessment for Thousand Oaks, California, Singapore, and Juncos, Puerto Rico sites to guide awareness and stakeholder engagement.

UNESCO World Heritage sites

(11.4.1) Indicate whether any of your organization's activities are located in or near to this type of area important for biodiversity

Select from:

☑ Yes (partial assessment)

(11.4.2) Comment

In 2023, Amgen performed an initial gap analysis aligned with the Taskforce for Nature-Related Financial Disclosures framework to better understand potential areas to further protect nature and biodiversity. We completed a screening-level biodiversity risk assessment for 17 Amgen facilities and six supplier sites. The sites represent ecologically diverse regions and critical operations at each step of Amgen's value chain. This assessment is helping Amgen determine possible site-specific biodiversity risks and opportunities and will form the foundation for prioritizing future action. In 2024, Amgen performed a WWF Biodiversity Risk Filter assessment to

identify prioritized, function-based site biodiversity risks and impacts for key sites. We also performed a multi-factor site biodiversity area species impact assessment for Thousand Oaks, California, Singapore, and Juncos, Puerto Rico sites to guide awareness and stakeholder engagement.

UNESCO Man and the Biosphere Reserves

(11.4.1) Indicate whether any of your organization's activities are located in or near to this type of area important for biodiversity

Select from:

☑ Yes (partial assessment)

(11.4.2) Comment

In 2023, Amgen performed an initial gap analysis aligned with the Taskforce for Nature-Related Financial Disclosures framework to better understand potential areas to further protect nature and biodiversity. We completed a screening-level biodiversity risk assessment for 17 Amgen facilities and six supplier sites. The sites represent ecologically diverse regions and critical operations at each step of Amgen's value chain. This assessment is helping Amgen determine possible site-specific biodiversity risks and opportunities and will form the foundation for prioritizing future action. In 2024, Amgen performed a WWF Biodiversity Risk Filter assessment to identify prioritized, function-based site biodiversity risks and impacts for key sites. We also performed a multi-factor site biodiversity area species impact assessment for Thousand Oaks, California, Singapore, and Juncos, Puerto Rico sites to guide awareness and stakeholder engagement.

Ramsar sites

(11.4.1) Indicate whether any of your organization's activities are located in or near to this type of area important for biodiversity

Select from:

☑ Yes (partial assessment)

(11.4.2) Comment

In 2023, Amgen performed an initial gap analysis aligned with the Taskforce for Nature-Related Financial Disclosures framework to better understand potential areas to further protect nature and biodiversity. We completed a screening-level biodiversity risk assessment for 17 Amgen facilities and six supplier sites. The sites represent ecologically diverse regions and critical operations at each step of Amgen's value chain. This assessment is helping Amgen determine possible site-specific biodiversity risks and opportunities and will form the foundation for prioritizing future action. In 2024, Amgen performed a WWF Biodiversity Risk Filter assessment to identify prioritized, function-based site biodiversity risks and impacts for key sites. We also performed a multi-factor site biodiversity area species impact assessment for Thousand Oaks, California, Singapore, and Juncos, Puerto Rico sites to guide awareness and stakeholder engagement.

Key Biodiversity Areas

(11.4.1) Indicate whether any of your organization's activities are located in or near to this type of area important for biodiversity

Select from:

☑ Yes (partial assessment)

(11.4.2) Comment

In 2023, Amgen performed an initial gap analysis aligned with the Taskforce for Nature-Related Financial Disclosures framework to better understand potential areas to further protect nature and biodiversity. We completed a screening-level biodiversity risk assessment for 17 Amgen facilities and six supplier sites. The sites represent ecologically diverse regions and critical operations at each step of Amgen's value chain. This assessment is helping Amgen determine possible site-specific biodiversity risks and opportunities and will form the foundation for prioritizing future action. In 2024, Amgen performed a WWF Biodiversity Risk Filter assessment to identify prioritized, function-based site biodiversity risks and impacts for key sites. We also performed a multi-factor site biodiversity area species impact assessment for Thousand Oaks, California, Singapore, and Juncos, Puerto Rico sites to guide awareness and stakeholder engagement.

Other areas important for biodiversity

(11.4.1) Indicate whether any of your organization's activities are located in or near to this type of area important for biodiversity

Select from:

☑ Yes (partial assessment)

(11.4.2) Comment

In 2023, Amgen performed an initial gap analysis aligned with the Taskforce for Nature-Related Financial Disclosures framework to better understand potential areas to further protect nature and biodiversity. We completed a screening-level biodiversity risk assessment for 17 Amgen facilities and six supplier sites. The sites represent ecologically diverse regions and critical operations at each step of Amgen's value chain. This assessment is helping Amgen determine possible site-specific biodiversity risks and opportunities and will form the foundation for prioritizing future action. In 2024, Amgen performed a WWF Biodiversity Risk Filter assessment to identify prioritized, function-based site biodiversity risks and impacts for key sites. We also performed a multi-factor site biodiversity area species impact assessment for Thousand Oaks, California, Singapore, and Juncos, Puerto Rico sites to guide awareness and stakeholder engagement.
[Fixed row]

C13. Further information & sign off

(13.1) Indicate if any environmental information included in your CDP response (not already reported in 7.9.1/2/3, 8.9.1/2/3/4, and 9.3.2) is verified and/or assured by a third party?

	Other environmental information included in your CDP response is verified and/or assured by a third party
	Select from: ☑ Yes

[Fixed row]

(13.1.1) Which data points within your CDP response are verified and/or assured by a third party, and which standards were used?

Row 1

(13.1.1.1) Environmental issue for which data has been verified and/or assured

Select all that apply

☑ Climate change

(13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Climate change

☑ All data points in module 7

(13.1.1.3) Verification/assurance standard

General standards

☑ ISAE 3000

(13.1.1.4) Further details of the third-party verification/assurance process

Amgen assures environmental sustainability (ES) data on an annual basis that includes +80 metrics in energy, carbon, water, waste, and safety by a third-party external auditor. Amgen's 2024 ES data assurance statement can be found on Amgen.com. These verified environmental data are used to respond to CDP questions. All data is housed in our environmental data management system and verified by two subject matter experts in global corporate engineering.

(13.1.1.5) Attach verification/assurance evidence/report (optional)

amgen-env-data-assurance-statement-2024.pdf

Row 2

(13.1.1.1) Environmental issue for which data has been verified and/or assured

Select all that apply

☑ Water

(13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Water security

☑ All data points in module 9

(13.1.1.3) Verification/assurance standard

General standards

☑ ISAE 3000

(13.1.1.4) Further details of the third-party verification/assurance process

Amgen assures environmental sustainability (ES) data on an annual basis that includes +80 metrics in energy, carbon, water, waste, and safety by a third-party external auditor. Amgen's 2024 ES data assurance statement can be found under the responsibilities on Amgen.com. These verified environmental data are used to respond to CDP questions. All data are housed in our environmental data management system and verified by two subject matter experts in global corporate engineering.

(13.1.1.5) Attach verification/assurance evidence/report (optional)

amgen-env-data-assurance-statement-2024.pdf
[Add row]

(13.2) Use this field to provide any additional information or context that you feel is relevant to your organization's response. Please note that this field is optional and is not scored.

	Additional information
	Not applicable

[Fixed row]

(13.3) Provide the following information for the person that has signed off (approved) your CDP response.

(13.3.1) Job title

Senior Director of Engineering

(13.3.2) Corresponding job category

Select from:
☑ Environment/Sustainability manager
[Fixed row]

(13.4) Please indicate your consent for CDP to share contact details with the Pacific Institute to support content for its Water Action Hub website.

Select from:

☑ Yes, CDP may share our Disclosure Submission Lead contact details with the Pacific Institute

Public